However, AstraZeneca on Saturday announced it has resumed the phase 3 trials after getting a nod from the Medicines Health Regulatory Authority (MHRA) in the UK.
On September 6, AstraZeneca announced that the standard review process in its ongoing trials of the vaccine candidate triggered a "voluntary pause to vaccination" across "all" global sites so that independent committees and worldwide regulators could review safety data related to the vaccine.
The Serum Institute of India is developing the vaccine in collaboration with AstraZeneca and Oxford University.
Chinese state-owned bio-pharm company Sinopharm, through its China National Biotec Group (CNBG) unit, has two inactivated vaccines. The DCGI has also asked SII to DSMB UK as well as DSMB India to obtain clearance for resumption of clinical trials.
Leading US and European vaccine developers have pledged to uphold scientific safety and efficacy standards for their experimental vaccines and not bow to political pressures to rush the process.
ICMR granted approval to KEM and Nair for Phase 2 and 3 clinical trials of Covishield last month.
Egypt's Health and Population Ministry announced that starting Sunday it would open volunteer registration for the third phase of the coronavirus vaccine clinical trials, done in cooperation with the Chinese government and the UAE health care company G42.
An AstraZeneca spokesperson confirmed the pause in vaccinations covered studies in the US and other countries. At least 8 candidate vaccines being developed in India.
On this, the data safety monitoring body has questioned that the patient, after the illness, these trials were stopped, give information about them.
Health Minister Greg Hunt says there is genuine hope a vaccine being developed in the United Kingdom will be available in the first half of next year.
The WHO's chief scientist said the pause in the trial should serve as a "wake-up" call that there would be ups and downs in the development of a vaccine.